This Article Abstract Full Text Full Text (PDF) Erratum (v37,p2012) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bahit, M. C. Articles by Granger, C. B. Search for Related Content PubMed PubMed Citation Articles by Bahit, M. C. Articles by Granger, C. B.

Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb

Maria Cecilia Bahit, MD^*, Eric J. Topol, MD, FACC, Robert M. Califf, MD, FACC^*, Paul W. Armstrong, MD, FACC, Douglas A. Criger, MPH^*, Vic Hasselblad, PhD^*, Amadeo Betriu, MD, Jack Hirsh, MD, FACC^||, Diego Ardissino, MD^¶ and Christopher B. Granger, MD, FACC^*

^* Duke Clinical Research Institute, Durham, North Carolina, USA
Cleveland Clinic Foundation, Cleveland, Ohio, USA
University of Alberta, Edmonton, Alberta, Canada
Hospital Clinic I, Barcelona, Spain
^|| McMaster University, Hamilton, Ontario, Canada
^¶ Ospedale Maggiore di Parma, Parma, Italy

View larger version (28K): [in a new window]   Figure 1 Derivation of study patient population, including comparison subgroups for (re)infarction [(re)MI] rates.

View larger version (17K): [in a new window]   Figure 2 Kaplan-Meier curves showing cumulative incidence of reinfarction in patients assigned to heparin (bold lines) or hirudin. (Left) Event rates during study drug infusion until discontinuation. (Middle) Event rates after study drug therapy discontinuation until 12 h. (Right) Event rates in period starting 12 h after antithrombin therapy discontinuation. At beginning of each period, event rates were (re) set at 0%. Any patient still alive contributes to event estimates in each period.

View larger version (14K): [in a new window]   Figure 3 Reinfarction rates per average 4-h time period in patients who received heparin (diamonds, solid lines) or hirudin (squares, dashed lines), according to time relative to study drug infusion. Solid figures are point estimates; vertical lines are 95% confidence intervals.